Phase II study of sunitinib malate following hepatic artery embolization for metastatic gastrointestinal neuroendocrine tumors.

Trial Profile

Phase II study of sunitinib malate following hepatic artery embolization for metastatic gastrointestinal neuroendocrine tumors.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2012

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Gastrointestinal cancer; Liver metastases
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Feb 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
    • 28 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Oct 2011 Planned End Date changed from 1 Dec 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top